Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C
Open accessAbstract
Lung cancers are the leading cause of cancer deaths worldwide and pose a grave threat to human life and health. Non-small cell lung cancer (NSCLC) is the most frequent malignancy occupying 80% of all lung cancer subtypes. Except for other mutations (e.g., KRASG12V/D) that are also vital for the occurrence, KRASG12C gene mutation is a significant driving force of NSCLC, with a prevalence of approximately 14% of all NSCLC patients. However, there are only a few therapeutic drugs targeting KRASG12C mutations currently. Here, we synthesized hydrocarbon-stapled peptide 3 that was much shorter and more stable with modest KRASG12C binding affinity and the same anti-tumor effect based on the α-helical peptide mimic SAH-SOS1A. The stapled peptide 3 effectively induced G2/M arrest and apoptosis, inhibiting cell growth in KRAS-mutated lung cancer cells via disrupting the KRAS-mediated RAF/MEK/ERK signaling, which was verified from the perspective of genomics and proteomics. Peptide 3 also exhibited strong anti-trypsin and anti-chymotrypsin abilities, as well as good plasma stability and human liver microsomal metabolic stability. Overall, peptide 3 retains the equivalent anti-tumor activity of SAH-SOS1A but with improved stability and affinity, superior to SAH-SOS1A. Our work offers a structural optimization approach of KRASG12C peptide inhibitors for cancer therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MRTX1133 treatment results in G2/M phase blockade in CRC cells.
“Furthermore, MRTX1133 treatment resulted in G2/M phase blockade in CRC cells (Fig. 1B), which is a typical consequence of KRAS mutant allele inhibition [17–19].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,708 · see citing works
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · see citing works
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903 · see citing works
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · see citing works
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · see citing works
Stapled Peptides for Intracellular Drug Targets
Verdine, G. L., & Hilinski, G. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00001-x · Cited by 433 · see citing works
Hillig, R. C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C. M., Werbeck, N. D., Briem, H., Boemer, U., Weiske, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812963116 · Cited by 388 · see citing works
Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis
Kim, Y.-W., Grossmann, T. N., & Verdine, G. L. (2011) · Nature Protocols · doi:10.1038/nprot.2011.324 · Cited by 376 · see citing works
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
Bird, G. H., Madani, N., Perry, A. F., Princiotto, A. M., Supko, J. G., He, X., Gavathiotis, E., Sodroski, J., & Walensky, L. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002713107 · Cited by 345 · see citing works
Assessing Helical Protein Interfaces for Inhibitor Design
Bullock, B. N., Jochim, A. L., & Arora, P. S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206074j · Cited by 298 · see citing works
An orthosteric inhibitor of the Ras-Sos interaction
Patgiri, A., Yadav, K. K., Arora, P. S., & Bar‐Sagi, D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.612 · Cited by 294 · see citing works
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271 · see citing works
Stapled Peptides—A Useful Improvement for Peptide-Based Drugs
Moiola, M., Memeo, M. G., & Quadrelli, P. (2019) · Molecules · doi:10.3390/molecules24203654 · Cited by 168 · see citing works
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
Leshchiner, E. S., Parkhitko, A. A., Bird, G. H., Luccarelli, J., Bellairs, J. A., Escudero, S., Opoku-Nsiah, K., Godes, M., Perrimon, N., & Walensky, L. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413185112 · Cited by 159 · see citing works
Inhibition of Ras Signaling by Blocking Ras–Effector Interactions with Cyclic Peptides
Upadhyaya, P., Qian, Z., Selner, N. G., Clippinger, S. R., Wu, Z., Briesewitz, R., & Pei, D. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201502763 · Cited by 149 · see citing works
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D. M., Dai, S., Shokat, K. M., & Suga, H. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00514 · Cited by 124 · see citing works
Trinh, T. B., Upadhyaya, P., Qian, Z., & Pei, D. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00164 · Cited by 119 · see citing works
Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes
Gade, T. P. F., Hassen, W., Santos, E. B., Gunset, G., Saudemont, A., Gong, M., Brentjens, R. J., Zhong, X.-S., Stephan, M. T., Stefanski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0436 · Cited by 117 · see citing works
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 115 · see citing works
Liu, M., Sjogren, A.-K. M., Karlsson, C., Ibrahim, M. X., Andersson, K., Olofsson, F. J., Wahlstrom, A. M., Dalin, M. G., Yu, H., Chen, Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908396107 · Cited by 113 · see citing works
Stapled peptide design: principles and roles of computation
Tan, Y. S., Lane, D. P., & Verma, C. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.012 · Cited by 111 · see citing works
ANNIVERSARY REVIEW: Octreotide, 40 years later
Lamberts, S. W. J., & Hofland, L. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0074 · Cited by 100 · see citing works
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 100 · see citing works
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Guillard, S., Kolasinska-Zwierz, P., Debreczeni, J. E., Breed, J., Zhang, J., Béry, N., Marwood, R., Tart, J., Overman, R., Stocki, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16111 · Cited by 97 · see citing works
Wang, J., Huang, X. F., & Li, F. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0387-3 · Cited by 95 · see citing works
Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide
Dougherty, P. G., Wen, J., Pan, X., Koley, A., Ren, J.-G., Sahni, A., Basu, R., Salim, H., Kubi, G. A., Qian, Z., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00456 · Cited by 83 · see citing works
Araghi, R. R., Bird, G. H., Ryan, J. A., Jenson, J. M., Godes, M., Pritz, J. R., Grant, R. A., Letai, A. G., Walensky, L. D., & Keating, A. E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712952115 · Cited by 80 · see citing works
Targeting Krasg12c‐mutant cancer with a mutation‐specific inhibitor
Christensen, J. G., Olson, P., Briere, T., Wiel, C., & Bergö, M. O. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13057 · Cited by 77 · see citing works
Clark, G. J., Drugan, J. K., Terrell, R. S., Bradham, C. A., Der, C. J., Bell, R. M., & Campbell, S. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1577 · Cited by 76 · see citing works
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 74 · see citing works
Inhibition of Ras–effector interactions by cyclic peptides
Wú, X., Upadhyaya, P., Villalona-Calero, M. A., Briesewitz, R., & Pei, D. (2012) · MedChemComm · doi:10.1039/c2md20329d · Cited by 69 · see citing works
Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
Luo, L., Li, Y., Liu, Z., Fan, X., Duan, F., Li, R., Yao, X., Leung, E. L., & Liu, L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00199 · Cited by 69 · see citing works
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67 · see citing works
Design of Cell-Permeable Stapled Peptides as HIV-1 Integrase Inhibitors
Long, Y., Huang, S.-X., Zawahir, Z., Xu, Z.-L., Li, H., Sanchez, T. W., Zhi, Y., Houwer, S. D., Christ, F., Debyser, Z., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4006516 · Cited by 48 · see citing works
Zhang, P., Ma, J., Zhang, Q., Jian, S., Sun, X., Liu, B., Nie, L., Liu, M., Liang, S., Zeng, Y., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00634 · Cited by 43 · see citing works
Ősapay, K., Tran, D., Ladokhin, A. S., White, S. H., Henschen, A., & Selsted, M. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.16.12017 · Cited by 37 · see citing works
Inhibition of Ral GTPases Using a Stapled Peptide Approach
Thomas, J. C., Cooper, J. M., Clayton, N. S., Wang, C., White, M. A., Abell, C., Owen, D., & Mott, H. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720243 · Cited by 25 · see citing works
Ruiz‐Santaquiteria, M., de Castro, S., Toro-Londoño, M., de Lucio, H., Gutiérrez, K. J., Sánchez‐Murcia, P. A., Jiménez, M. A., Gago, F., Jiménez-Ruı́z, A., Camarasa, M., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.071 · Cited by 23 · see citing works
Cheng, H., & Planken, S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00311 · Cited by 23 · see citing works
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.
de Castro, J., & Belda-Iniesta, C. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.07 · Cited by 22 · see citing works
A New Methodology for Incorporating Chiral Linkers into Stapled Peptides
Serrano, J. C., Sipthorp, J., Xu, W., Itzhaki, L. S., & Ley, S. V. (2017) · ChemBioChem · doi:10.1002/cbic.201700075 · Cited by 22 · see citing works
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants
Han, C. W., Jeong, M. S., Ha, S. C., & Jang, S. B. (2020) · Cancers · doi:10.3390/cancers12061412 · Cited by 20 · see citing works
Wallbrecher, R., Chêne, P., Ruetz, S., Stachyra, T., Vorherr, T. E., & Brock, R. E. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13834 · Cited by 20 · see citing works
A Novel Methodology for the Incorporation of Chiral Linkers in Stapled Peptides
Serrano, J., Sipthorp, J., Xu, W., Itzhaki, L. S., & Ley, S. V. (2017) · Apollo (University of Cambridge) · doi:10.17863/cam.8979 · Cited by 19 · see citing works
A Chemical-Intervention Strategy To Circumvent Peptide Hydrolysis by d -Stereoselective Peptidases
Bann, S. J., Ballantine, R. D., McCallion, C. E., Qian, P., Li, Y., & Cochrane, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01078 · Cited by 15 · see citing works
Xu, L., Li, C., An, L.-Y., Dai, Z., Chen, X., You, Q., Hu, C., & Di, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111844 · Cited by 15 · see citing works
Self-citationMcNew, K. L., Whipple, W. J., Mehta, A. K., Grant, T. J., Ray, L. C., Kenny, C. J., & Singh, A. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0173 · Cited by 11 · see citing works
Chang, C.-Y., Lin, C.-W., Chiang, S.-K., Chen, P.-L., Huang, C., Liu, S., Chong, P. C.-S., & Huang, M. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400081f · Cited by 8 · see citing works
Inhibition of K-Ras4B-plasma membrane association with a membrane microdomain-targeting peptide
Li, F.-Y., Zhang, Z., Voß, S., Wu, Y., Zhao, Y., Li, Y., & Chen, Y. (2019) · Chemical Science · doi:10.1039/c9sc04726c · Cited by 8 · see citing works
Schreier, V. N., Mező, G., Orbán, E., Dürr, C., Marquardt, A., & Manea, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.114 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95 · see citing works
Guo, Y., Li, T., Gong, B., Hu, Y., Wang, S., Yang, L., & Zheng, C. (2024) · Advanced Science · doi:10.1002/advs.202408069 · Cited by 47 · see citing works
Jiang, X., Jiang, S., Huang, H., Li, D., Yang, R., Yang, Y., Wang, D., Song, B., & Chen, Z. (2022) · Phytopathology · doi:10.1094/phyto-11-21-0457-r · Cited by 33 · see citing works
Peptide Stapling Applied to Antimicrobial Peptides
Lourenço, A. L. P., Rios, T. B., da Silva, Á. P., Franco, O. L., & Ramada, M. H. S. (2023) · Antibiotics · doi:10.3390/antibiotics12091400 · Cited by 31 · see citing works
High-Throughput Screening of Stapled Helical Peptides in Drug Discovery
Zhang, Y., Guo, J., Cheng, J., Zhang, Z., Kang, F., Wu, X., & Chu, Q. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01541 · Cited by 29 · see citing works
He, H., Chen, R., Wang, Z., Qing, L., Zhang, Y., Liu, Y., Pan, W., Fang, H., & Zhang, S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106536 · Cited by 16 · see citing works
Sviridov, D. O., Dasseux, A., Reimund, M., Pryor, M., Drake, S. K., Jarin, Z., Wolska, A. T., Pastor, R. W., & Remaley, A. T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1223920 · Cited by 9 · see citing works
Chen, B., Li, Y., Bai, H., Ji, Y., Cong, W., Hu, H., & He, S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106770 · Cited by 9 · see citing works
Recent advances, strategies, and future perspectives of peptide-based drugs in clinical applications
Yang, Q., Hu, Z., Jiang, H., Wang, J., Han, H., Shi, W., & Qian, H. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60800-4 · Cited by 10 · see citing works
Sampaio, J. G., Pressete, C. G., Costa, A. V., Martins, F. T., Lima, G. D. D. A., Ionta, M., & Teixeira, R. R. (2023) · Life · doi:10.3390/life13071428 · Cited by 8 · see citing works
Peptide inhibitors targeting Ras and Ras-associated protein–protein interactions
Han, D., Li, A., Zhu, L., Zhuang, C., Zhao, Q., & Zou, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116878 · Cited by 7 · see citing works
Chemical Strategies towards the Development of Effective Anticancer Peptides
Li, C., & Jin, K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230426111157 · Cited by 6 · see citing works
Self-citationEditorial of Special Column “Novel Peptides and Peptidomimetics in Drug Discovery”
Cai, J., & Wei, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.023 · Cited by 6 · see citing works
Yang, X., Zhang, S., Yang, Y., Duan, X., & Li, X. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241264853 · Cited by 1 · see citing works
Peng, Z., Chen, L., Miao, X., Wang, Q., Fu, S., Zhang, X., Zhou, X. L., Ren, S., Lao, Y., Li, Y., et al. (2025) · Journal of Peptide Science · doi:10.1002/psc.70047 · Cited by 1 · see citing works
Stapled peptides for new drug discovery
Liu, C., Wang, N., Chen, B., & Hu, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00003-6
Advances in peptide-based drug discovery
Khatri, B., Velloso, J. P. L., Shambhawi, Kan, M., & Craik, D. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00041-8
Targeting the Undruggable: Deep Learning-Driven Design of Peptide Therapeutics in Cancer
Nguyen, H. T. N., Le, B. H. N., Van, N. T. H., Tran, T. T. T., & Nguyen, T. M. (2026) · Pharmaceuticals · doi:10.3390/ph19070998
Ashrafizadeh, M., Nabavi, N., & Xu, Y. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i3.36
BindingDB (2026) · UC San Diego · doi:10.7270/q2t4401d
- Authors
- Li, C., Zhao, N., An, L., Dai, Z., Chen, X., Yang, F., You, Q., Di, B., Hu, C., & Xu, L.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Di, Bin
- Hu, Chi
- Xu, Lili
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 11
- Issue
- 9
- Pages
- 2670-2684
- ISSN
- 2211-3835 (ISSN-L)
- PMC
- PMC8463269
- OpenAlex
- W3174916617
- Cited by
- 20
- References
- 52
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 8 · 2022: 2 · 2021: 1
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Acta Pharmaceutica Sinica B (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81773693, 81803354)
- Natural Science Foundation of Jiangsu Province (BK20180564)
- Fundamental Research Funds for the Central Universities (2632021ZD13)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Materials Science › Biomaterials › Supramolecular Self-Assembly in Materials
- Keywords
- hydrocarbon-stapled peptides, KRAS G12C, non-small cell lung cancer, apoptosis, G2/M cell cycle arrest, MAPK/ERK pathway, peptide stability, plasma stability, liver microsomal metabolism, KRAS inhibitors, structural optimization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
